ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy
A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge's ELP Platform (Elastin Like Polypeptide Platform), a long-acting...
Nippon Shinyaku Releases First Clinical Trial (First in Human) of Brogidirsen NS-089/NCNP-02 for the Treatment of Duchenne
The National Center of Neurology and Psychiatry is announced the publication of a research paper in Cell Reports Medicine detailing the results of an...
What is Ataluren (Translarna)? What is Ataluren Used For?
Ataluren (Translarna) is an investigational drug used to delay disease progression in outpatients with Duchenne muscular dystrophy (DMD), a progressive and fatal neuromuscular disease....
Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy
The results of new gene therapy studies for Duchenne muscular dystrophy disease will be watched by curious eyes in 2025. The trial phases of...
What is Deramiocel? What Does CAP-1002 Do?
Capricor Therapeutics, a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the completion of the submission...